Protect the healthy cells, expose the cancer
We aim to cure blood cancers through cell and genome engineering
The Science
Our novel approach aims to transform blood cancer treatment.
Vor Bio is developing a proprietary platform built on Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T Cells.
Our Approach
Treatment-resistant HSCTs potentially enable curative targeted therapy opportunities for blood cancers
We aren’t inventing new technologies. We’re applying the latest scientific advancements to fight AML in a new way.
The Vor Bio Platform
We are working to cure AML and then go further
Our proprietary platform combines genome engineering, Hematopoietic Stem Cell (HSC) biology, and CAR-T cells to solve urgent unmet medical needs for patients with blood cancers.
Understanding Our Impact
For Patients & Caregivers
Our Investigational Program
We aim to transform treatment by protecting the healthy blood cells and only attacking the cancer cells with targeted therapies post-transplant.
Our Clinical Trial
We are currently conducting a clinical trial to further investigate our promising approach.
Patient / Donor Journey
Our approach genetically edits HSCs from a healthy matched donor to be resistant to targeted therapies in the patient post-transplant.
The Science Behind Our Approach
For Medical Professionals
Our Investigational Program
By protecting healthy cells, we are aiming to delay or prevent relapse and enable cures for patients with AML and other blood cancers.
Clinical Trials
Our Phase 1/2a clinical trial is actively recruiting patients.
Join Our Team
Passion. Fellowship. Humility.
Come be a part of a team that is developing a unique approach to one of medicine’s greatest challenges—eradicating cancer.